Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Issue of equity shares ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Novelix Pharmaceuticals has informed BSE that its Board meeting is scheduled for May 29, 2026. Key agenda items include: approval of Q4 and full year FY2026 standalone financial results (ending March 31, 2026), allotment of equity shares upon conversion of warrants, appointment of Internal Auditor for FY 2026-27, and most notably, issuance of securities on a preferential basis. The company will also discuss adopting the EGM notice and fixing its date, time, and venue. An E-voting scrutinizer will be appointed. The trading window remains closed for designated persons until 48 hours after the board meeting concludes.
The preferential securities issuance and warrant conversion will dilute existing shareholding. However, fresh capital infusion could fund growth. The Q4/FY2026 results approval on May 29 could be a near-term catalyst for the stock. Shareholders should watch for EGM details regarding the size and pricing of the preferential issue.